Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationAtmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer.Redefining hormone resistance in prostate cancer.5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Update on the management of prostate cancer with goserelin acetate: patient perspectivesAbiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.An update on the changing indications for androgen deprivation therapy for prostate cancer.Emerging drugs for prostate cancer.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.5α-reductase type 3 enzyme in benign and malignant prostate.Cholesterol as a potential target for castration-resistant prostate cancer.Androgen suppression strategies for prostate cancer: is there an ideal approach?The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.The role of abiraterone in the management of metastatic castration-resistant prostate cancer.Concept and viability of androgen annihilation for advanced prostate cancer.SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.Androgen synthesis in prostate cancer: do all roads lead to Rome?Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.Androgen Signaling in Prostate Cancer.Castration-resistant prostate cancer: targeted therapies and individualized treatmentA Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate CancerClinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.Leveraging the species barrier to advance cancer therapy.Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.
P2860
Q21285041-08DE8101-CA26-41CC-ADBB-80847D3D261DQ27007208-6EA11353-CC93-4E37-8C0B-906606F5E4DFQ33446864-5A7A4BF5-9CB9-4EA6-ADBB-C58D0E3C67A9Q33903836-2BC4CA4D-F32D-431B-8412-AAC54B34482CQ34183936-70522556-66DE-4DFF-B67E-77C33852B2B3Q34204078-48ED3425-26D2-41EA-94BC-FDAD2A4B6A3BQ34294888-CB819122-1705-4476-B292-AE68E9712465Q34418403-708AA679-4473-43CD-AAFB-8D7B2DFB53A0Q34619574-1FD7576E-3A10-4687-B700-9648B98BA41DQ35223874-087513B9-8988-40D1-854C-24346CDDC2DFQ35549863-5FC0142E-F5E2-411F-B534-09867EC79733Q37570555-8E9CDCCB-B898-40CA-B8F1-B8725EA0CB5FQ37709925-DC212FA5-1476-44D6-B259-BCF7756A737FQ37712234-CF344DAB-D7C0-4BBE-9630-02B97AB7D954Q37777663-75509031-B1C7-4CAA-9F61-DA60E7A79FBBQ37850714-5387D11A-3E40-4664-ABA7-9CB8C9D61C9EQ37953805-1D118545-2781-4BC6-8C2B-A0A03C42CC7CQ38002465-3B0BEB37-2440-41C7-B3B8-6949FA0159E8Q38207556-6F06B63D-24AF-4B46-9111-20074B729374Q38862028-40C78DEF-112C-4536-8B95-40B40F5A5804Q39002780-4AEF3699-21A0-435B-BDAB-9DFB4BF1977DQ39176498-FA04B8C9-28DF-4BCB-9874-2B5929362171Q39227656-6EF248DD-516B-4121-9C59-D33AA582A5E6Q39511732-32BECCED-1264-432C-A024-ED3B7B406301Q42174990-6EBF45F0-FD96-4CD2-AFD6-28A709BDB3F4Q44938966-C63FC5C9-CCAD-4181-B132-4FBF608EA339Q45758959-506DD535-F6FC-46B6-AF97-E6D2C7247C4EQ52655045-E6C415DF-E6B9-498C-9010-BDCC32956376
P2860
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II study of Dutasteride ...... g androgen deprivation therapy
@ast
Phase II study of Dutasteride ...... g androgen deprivation therapy
@en
type
label
Phase II study of Dutasteride ...... g androgen deprivation therapy
@ast
Phase II study of Dutasteride ...... g androgen deprivation therapy
@en
prefLabel
Phase II study of Dutasteride ...... g androgen deprivation therapy
@ast
Phase II study of Dutasteride ...... g androgen deprivation therapy
@en
P2093
P2860
P1476
Phase II study of Dutasteride ...... g androgen deprivation therapy
@en
P2093
Donald L Trump
Gregory E Wilding
James L Mohler
Oliver Sartor
Satyan K Shah
P2860
P304
P356
10.1016/J.JURO.2008.10.014
P407
P577
2008-12-16T00:00:00Z